LETTERS 2000 Vol. 2, No. 7 891–894

ORGANIC

Total Synthesis of Fully Acetylated *N*-Acetylneuraminic Acid (Neu5Ac), 2-Deoxy-β-Neu5Ac, and 4-*epi*-2-Deoxy-β-Neu5Ac from D-glucose

Lian-Sheng Li, Yu-Lin Wu,* and Yikang Wu

State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

ylwu@pub.sioc.ac.cn

Received January 12, 2000

ABSTRACT



Sialic acid and its analogues have been synthesized using a salenCo(II) complex catalyzed hetero Diels–Alder reaction and oxidative azidation (CAN/NaN₃) of silyl enol ether as the key steps.

Sialic acids (especially *N*-acetylneuraminic acid, Neu5Ac 1) frequently occur at the terminal end of glycoconjugates, such as glycoproteins, glycolipids, and oligosaccharides, in cell membranes and nerve tissues of various living organisms.¹ They play a vital role² in numerous biological processes including cell-to-cell recognition, cell-adhesion, and tumor metastasis. Among the analogues of 1, *N*-acetyl-2-deoxy-neuraminic acid (2) and its 4-epimer are of particular interest, because they are inhibitors of Neu5Ac-associated enzymes such as *Vibio cholerae* sialidase³ and influenza viral neuraminidase.⁴ Considerable attention has therefore been paid to developing effective methods for synthesis of both Neu5Ac (1)^{5,6} and its 2-deoxy-2-H derivative (2).^{3,6d,7} Herein we wish to report an efficient approach to *N*-acetylneuraminic acid

(Neu5Ac), 2-deoxy- β -Neu5Ac, and 4-*epi*-2-deoxy- β -Neu5Ac from D-glucose based on salenCo(II) (**3**) complex⁸ catalyzed hetero Diels-Alder reactions.



The desired silvloxy diene **8** was prepared from the readily available D-glucose as shown in Scheme 1. Thus, 2,4-O-ethylidene-D-erythrose (**5**) was obtained using the established procedures.⁹ Wittig reaction of **5** with Ph₃P=CHCOCH₃ afforded unsaturated ketone **6**, which was then protected as

⁽¹⁾ Gottschalk, A. Nature 1951, 167, 845.

⁽²⁾ von Itzstein, M.; Thompson, R. J. Top. Curr. Chem. 1997, 186, 119–170 and references therein.

⁽³⁾ Wallimann, K.; Vasella, A. *Helv. Chim. Acta* 1991, 74, 1520–1532.
(4) Flashner, M.; Kessler, J.; Tanenbaum, St. W. *Arch. Biochem. Biophys.* 1983, 221, 188.

⁽⁵⁾ For reviews, see: (a) Tuppy, H.; Gottschalk, A. The Structure of sialic acids and their quantitation. In *Glycoproteins. Their composition, structure and function*; Gottschalk, A., Ed.; Elsevier: Amsterdam, 1972; p 403. (b) DeNinno, M. P. *Synthesis* **1991**, 583–593. For recently reported chemical synthesis of Neu5Ac and related compounds, see: (c) Banwell, M.; Savi, C. D.; Watson, K. J. Chem. Soc., Perkin Trans. 1 **1998**, 2251–2252. (d) Takahashi, T.; Tsukamoto, H.; Kurosaki, M.; Yamada, H. Synlett

¹⁹⁹⁷, 1065–1066. (e) Chan, T.-H.; Lee, M.-C. J. Org. Chem. **1995**, 60, 4228–4232. (f) Gordon, D. M.; Whitesides, G. M. J. Org. Chem. **1993**, 58, 7937–7938. (g) Yamamoto, T.; Teshima, T.; Inami, K.; Shiba, T. Tetrahedron Lett. **1992**, 33, 325–328. (h) Csuk, R.; Hugener, M.; Vasella, A. Helv. Chim. Acta **1988**, 71, 609. (i) Danishefsky, S. J.; DeNinno, M. P.; Chen, S.-H. J. Am. Chem. Soc. **1988**, 110, 3929–3940. (j) Julina, R.; Müller, I.; Vasella, A.; Wyler, R. Carbohydr. Res. **1987**, 164, 415. (k) Baumberger, F.; Vasella, A. Helv. Chim. Acta. **1986**, 69, 1205–1215. (l) Danishefsky, S. J.; DeNinno, M. P. J. Org. Chem. **1986**, 2615–2617.



^{*a*} Reagents and conditions: (a) Paraldehyde, cat. H₂SO₄, 43%; (b) NaIO₄, NaHCO₃, H₂O; (c) Ph₃P=CHCOCH₃, toluene, 90 °C, 66% over two steps; (d) methylal, cat. P₂O₅, CHCl₃, 0 °C \rightarrow room temperature, 88%; (e) TBSOT_f, Et₃N, 0 °C, 99%; (f) ethyl glyoxylate, **3** (10% mol), CH₂Cl₂, room temperature, 62%.

MOM ether **7** (88% yield). Treatment of compound **7** with triflate and triethylamine at 0 °C for 30 min provided the corresponding diene **8** in 99% yield. The hetero Diels–Alder

reaction between compound **8** and ethyl glyoxylate (freshly distilled) catalyzed by (*S*,*S*)-salenCo(II) complex (**3**) (10% mol) at room temperature afforded cycloaddition product **9** in 62% isolated yield, along with a small amount of an isomer (<5% yield) and the byproducts¹⁰ from the Mukai-yama reaction.

The next key step of our synthesis was to introduce an amine group at the C-5. We first tried to prepare α -hydroxy ketone 10 by an AD reaction¹¹ of 9 under conditions similar to those used previously^{8d} (Scheme 2). 10 was then transformed in parallel into mesylate 11, tosylate 12, or triflate 13 and treated separately with NaN₃. To our surprise, the anticipated S_N2 reaction leading to 17 did not occur. Instead, all runs gave predominantly the elimination product, presumably due to the steric crowding caused¹² by the larger substituent at C-6. We then tested the Mitsunobu reaction¹³ (using DEAD, DPPA, Ph₃P); the reaction was very complicated. The Sharpless asymmetric aminohydroxylation reaction¹⁴ [LiOH/AcNHBr/K₂Os(OH)₄O₂ in *t*-BuOH/H₂O] of **9** did not afford any 15 either. The Evans' copper-mediated aziridination reaction¹⁵ gave the expected α -amino ketone adduct 14 in 39% isolated yield, when 9 was treated with 10 mol % of CuClO₄¹⁶ or Cu(OTf)₂ and 1.5 equiv (with respect to 9) of PhI=NTs¹⁷ in anhydrous MeCN at -30 °C.



^{*a*} Reagents and conditions: (a) $K_2OsO_2(OH)_4$ (5% mol), $(DHQD)_2$ –PHAL (5% mol), $NaHCO_3$ (3 equiv), K_2CO_3 (3 equiv), $K_3Fe(CN)_6$ (3 equiv), t-BuOH/H₂O (1:1), 0 °C, 78%; (b) NaN₃ (3 equiv), CAN (2.5 equiv), CH₃CN, -25 °C, 61%; (c) PhI=NTs (1 equiv), Cu(CH₃CN)_4CIO_4 (10% mol), CH₃CN, -20 \rightarrow -10 °C, 39%; (d) Na/NH₃, or Na/naphthalene, THF, -78 °C, \leq 10%; (e) CH₃COSH, room temperature, 90%; (f) NaBH₄, EtOH, -30 °C, 85%; (g) *p*-TsOH (2 equiv), EtOH, reflux, then Ac₂O, Et₃N, DMAP, CH₂Cl₂, 96%; (h) LiAl[O(CH₃)₃]₃H, THF, -10 °C, 80%; (i) MOMCl, *i*-Pr₂NEt, CH₂Cl₂, 91%; (j) H₂, Pd/C (10%), room temperature, then Ac₂O, Et₃N, DMAP, CH₂Cl₂, 95%; (k) same as (g), 92%.

Scheme 3^a



^a Reagents and conditions: (a) NaBH₄, EtOH, -30 °C, 83%; (b) MOMCl, *i*-Pr₂NEt, CH₂Cl₂, 0 °C \rightarrow room temperature, 90% (c) LDA, MoOPH, THF, -78 °C, 50%; (d) Ac₂O, Py, DMAP, CH₂Cl₂, room temperature, 84%; (e) H₂, Pd/C (10%), EtOH, 30 °C, then Ac₂O, Et₃N, DMAP, CH₂Cl₂, room temperature, 68%; (f) p-TsOH, EtOH, reflux, then Ac₂O, Py, DMAP, CH₂Cl₂, room temperature, 73%.

However, the following removal of the tosyl group in 14 using either Na/NH₃ or Na/naphthalene suffered from very low yield (<10%), although the expected product 15 did form. This difficulty made us reconsider introducing an azide group at C-5 first.

Oxidative azidation (CAN/NaN3) of silyl enol ether is also an established means to prepare α -azido ketone. Although there are reports^{18,19} on the ineffectiveness of this reaction, we found that the yield could be significantly improved by modifying the procedure. Thus, treatment of 9 with NaN₃ (3.0 equiv) in anhydrous CH₃CN at -25 °C followed by slow addition of CAN (2.5 equiv in CH₃CN) led to the desired product 17 in a 61% isolated yield, together with a small amount of 18 (10%). It is noteworthy that unlike all the previously reported procedures, the present one can be run easily on larger scales (1.5-2.5 g) without lowering the vield.

Conversion of 17 to the corresponding acetamide 15 using a modification of Rosen's method²⁰ (Scheme 2) was realized

(7) Chemical synthesis of 2-deoxy-2H derivatives of Neu5Ac: (a) Gervay, J.; Gregar, T. Tetrahedron Lett. 1997, 38, 5921-5924. (b) Bandgar, B. P.; Zbiral, E. Carbohydr. Res. 1995, 270, 201-210. (c) Wallimann, K.; Vasella, A. Helv. Chim. Acta 1990, 73, 1359-1372. (d) Bandgar, B. P.; Hartmann, M.; Schmid, W.; Zbiral, E. Liebigs Ann. Chem. 1990, 1185-1195. (e) Schmid, W.; Christian, R.; Zbiral, E. Tetrahedron Lett. 1988, 29, 3643-3646.

(8) (a) Hu, Y.-J.; Huang, X.-D.; Yao, Z.-J.; Wu, Y.-L. J. Org. Chem. 1998, 63, 2456-2461. (b) Li, L.-Sh.; Wu, Y.-K.; Hu, Y.-J.; Wu, Y.-L. Tetrahedron: Asymmetry 1998, 9, 2271-2277. (c) Hu, Y.-J.; Huang, X.-D.; Wu, Y.-L. J. Carbohydr. Chem. 1998, 17, 1095. (d) Li, L.-Sh.; Wu, Y.-K.; Wu, Y.-L. J. Carbohydr. Chem. 1999, 18, 1067-1077.

(9) Barker, R.; MacDonnald, D. L. J. Am. Chem. Soc. 1960, 82, 2301-2303

(10) For discussion about the mechanism of related reactions catalyzed by other salen metal complex catalysts, see: Schaus, S. E.; Brnalt, J.; Jacobsen, E. N. J. Org. Chem. 1998, 63, 403.

(11) (a) Hashiyama, T.; Morikawa, K.; Sharpless, K. B. J. Org. Chem. 1992, 57, 5067-5068. (b) Morikawa, K.; Park, J.; Andersson, P. G.; Hashiyama, T.; Sharpless, K. B. J. Am. Chem. Soc. 1993, 115, 8463-8064.

(12) Neufellner, E.; Kapeller, H.; Griengl, H. Tetrahedron 1998, 54, 11043-11062.

(13) Mitsunobu, O. Synthesis 1981, 1-28.

in 90% yield. Reduction of the ketone of 15 with NaBH₄ at -30 °C afforded the desired *anti* product **19** in 85% yield. All the protecting groups in compound **19** were then removed by treatment with *p*-TsOH in refluxing EtOH. Acetylation of the unmasked hydroxyl groups to afford the corresponding acetate 20²¹ was fulfilled (96%) using acetic anhydride in the presence of Et₃N and a catalytic amount of DMAP.

The 4-epi analogue 24 was also prepared according to Scheme 2. Reduction of the ketone carbonyl in 17 with the bulky reducing reagent LiAl[O(CH₃)₃]₃H²² at -10 °C gave syn product 21 in 80% isolated yield. After protection of the C-4 hydroxyl as the MOM ether (22, 91% yield), the azido functionality was hydrogenated to give an amine, which was converted to 23 in high yield (95%). Then, under the same conditions, compound 23 was transformed into 24, the fully acetylated 4-epi-2-deoxy-β-Neu5Ac, in 92% yield.²³

The total synthesis of sialic acid from intermediate 17 require oxidation at C-2. Thus, reduction of the ketone,

(15) Evans, D. A.; Faul, M. M.; Bilodeau, M. T. J. Am. Chem. Soc. 1994, 116, 2742-2753.

(16) The catalyst was prepared from Cu₂O according to the reported procedure: Kubas, G. J. Inorg. Synth. 1979, 19, 90-92.

(17) The I-N ylide was prepared by following the reported procedure: Yamada, Y.; Yamamoto, T.; Okawara, M. Chem. Lett. 1975, 361-362.

(18) Auberson, Y.; Vogel, P. Tetrahedron 1990, 46, 7019-7032

(19) Magnus, P.; Barth, L. Tetrahedron Lett. 1992, 33, 2777-2780.

(20) Rosen, T.; Lico, I. M.; Chu, D. T. W. J. Org. Chem. 1988, 53, 1580 - 1582

(21) NMR data for compound 20: ¹H NMR (300 MHz, CDCl₃) δ 5.59 $(1H, d, J = 8.5 \text{ Hz}, \text{NH}), 5.42 (1H, ddd, J = 7.1, 5.1, 1.2 \text{ Hz}), 5.25 (1H, ddd, J = 7.1, 5.1, 1.2 \text{ Hz$ dd, J = 4.7, 1.6 Hz), 5.11 (1H, ddd, J = 5.1, dt, J = 11.5, 4.9 Hz), 4.60 (1H, dd, J = 12.1, 2.2 Hz), 4.29 (1H, dd, J = 12.3, 6.9 Hz), 4.22 (2H, dq, J = 7.1, 1.3 Hz), 4.05 (1H, dd, J = 12.1, 2.2 Hz), 3.95 (1H, q, J = 10.2Hz), 3.67 (1H, J = 10.6, 1.4 Hz), 2.39 (1H, ddd, J = 12.6, 4.9, 2.2 Hz), 2.11, 2.10, 2.06, 2.05, 1.98 (15H, 5s), 1.76 (1H, q, J = 12.1 Hz), 1.28 (3H, t, J = 7.1 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 170.81, 170.64, 170.31, 170.25, 170.08, 168.71, 78.70, 74.12, 71.40, 70.82, 69.85, 62.73, 61.50, 51.84, 33.78, 23.24, 21.01, 20.94, 20.91, 20.72, 14.00; EIMS (m/z) 490 $(M^++1); [\alpha]_D = 34.2 (c \ 0.25, CHCl_3).$

(22) Boireau, G.; Deberly, A.; Toneva, R. *Synlett* **1993**, 585–587. (23) NMR data for compound **24**: ¹H NMR (600 MHz, CDCl₃) δ 5.82 (1H, d, J = 9.0 Hz, NH), 5.43 (1H, dt, J = 9.0, 2.4 Hz), 5.26 (1H, dd, J = 6.6, 3.0 Hz), 5.10 (1H, m), 4.47 (1H, dd, J = 12.6, 2.4 Hz), 4.43 (1H, dd, J = 6.6, 2.4 Hz), 4.28-4.22 (3H, m), 4.12 (1H, t, J = 7.2 Hz), 4.14-4.11 (1H, m), 2.52 (1H, ddd, J = 15.0, 4.2, 2.4 Hz), 2.17, 2.12, 2.05, 2.04, 2.01 (15H, 5s), 2.09 (1H, ddd, J = 15.0, 7.2, 3.0 Hz), 1.26 (3H, t, J = 7.1 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 171.08, 171.05, 170.62, 170.38, 170.23, 169.42, 70.83, 70.65, 69.37, 68.78, 62.38, 61.19, 60.35, 47.24, 30.08, 23.19, 20.96, 20.91, 20.75, 20.69, 13.69; EIMS (m/z) 490 $(M^+ + 1)$; $[\alpha]_D = 98.6$ (c 1.09, CHCl₃).

⁽⁶⁾ Enzyme synthesis of Neu5Ac and related compounds: (a) Bednarski, M. D.; Chenault, H. K.; Simon, E. S.; Whitesides, G. M. J. Am. Chem. Soc. 1987, 109, 1283-1285. (b) Auge, C.; David, S.; Gautheron, C. Tetrahedron Lett. 1984, 25, 4663-4664. (c) Auge, C.; David, S.; Gautheron, C.; Veyrières, A. Tetrahedron Lett. 1985, 26, 2439-2440. (d) Kim, M.-J.; Hennen, W. J.; Sweers, H. M.; Wong, C.-H. J. Am. Chem. Soc. 1988, 110, 6481-6486. (e) Wong, C.-H.; Whitesides, G. M. Enzymes in Synthetic Organic Chemistry, Tetrahedron Organic Chemistry Series Volume 12; Pergamon: Oxford, 1994. (f) Sugai, T.; Kuboki, A.; Hiramatsu, S.; Okazaki, H.; Ohta, H. Bull. Chem. Soc. Jpn. 1995, 68, 3581.

^{(14) (}a) Phukan, P.; Sudalai, A. Tetrahedron: Asymmetry 1998, 9, 1001-1005. (b) Bruncko, M.; Schlingloff, G.; Sharpless, K. B. Angew. Chem., Int. Ed. Engl. 1997, 36, 1483-1486.

following protection of the resulting hydroxy, furnished the desired *anti*-azido MOM ether **26** (Scheme 3). Oxidation of the lithium enolate of **26** with MoO₅•Py•HMPA (MoOPH)²⁴ gave the 2- α -OH product (along with traces of the 2- β -OH isomer) in 50% isolated yield (70%, based on recovered **26**). Acetylation of the hydroxyl at C-2 afforded compound **28** (84%). Then following a procedure similar to that described above, **28** was transformed into pentaacetylated ethyl ester

30.²⁵ The physical data of our synthetic sample are identical to those reported^{5f} by Whitesides.

In summary, we have established an effective synthesis of both sialic acid and its analogues. Further studies on the total synthesis of Neu2en5Ac and Zanamivir²⁶ (GG167) are currently ongoing in this laboratory, and the results will be reported in due time.

Acknowledgment. We thank the Chinese Academy of Sciences (KJ-952-S1-503, KJ-95-A1-504), the Chinese Natural Science Foundation (29790126, 29872049), and the State Ministry of Science and Technology of China (970211006-6) for financial support.

OL0055418

⁽²⁴⁾ Recently, Burke reported that the total synthesis of KDO from 2-deoxy-KDO used MoOPH as the oxidant: Burke, S. D.; Sametz, G. M. *Org. Lett.* **1999**, *1*, 71–74. The MoOPH was prepared according to the reported procedure: Vedejs, E.; Larsen, S. *Org. Synth.* **1986**, *64*, 127–137.

⁽²⁵⁾ NMR data of compound **30**: ¹H NMR (300 MHz, CDCl₃) δ 5.61 (1H, d, J = 9.3 Hz, NH), 5.49 (1H, ddd, J = 10.4, 5.8, 3.6 Hz), 5.26 (1H, dd, J = 5.0, 1.6 Hz), 5.22–5.18 (1H, m), 4.63 (1H, dd, J = 12.4, 2.5 Hz), 4.29 (1H, dd, J = 9.0, 7.9 Hz), 4.23 (2H, q, J = 7.1 Hz), 4.12 (1H, q, J = 10.2 Hz), 3.75 (1H, dd, J = 10.9, 1.9 Hz), 2.36 (1H, dd, J = 13.5, 4.9 Hz), 1.85 (1H, dd, J = 13.5, 11.2 Hz), 2.09, 2.08, 2.05, 2.04, 2.03, 1.98 (18H, 6s), 1.29 (3H, t, J = 7.1 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 171.08, 170.75, 170.29 × 2, 170.03, 169.76, 167.29, 98.31, 73.19, 71.25, 69.65, 68.79, 62.83, 61.96, 51.34, 37.53, 23.20, 20.98, 20.91, 20.79, 20.74, 14.00; [α]_D = 40.4 (c 0.52, CHCl₃).

^{(26) (}a) von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. *Nature* **1993**, *363*, 418–423. (b) Hayden, F. G.; Treanor, J. J.; Betts, R. F.; Lobo, M.; Esinhart, J.; Hussey, E. J. Am. Med. Assoc. **1996**, *275*, 295.